R&D Program For 1998-2002

6 November 1997

The proposed Fifth Framework Program for R&D for 1998-2002, submitted bythe Commission before the summer, is now under discussion in the European Parliament's Research Committee.

The Parliament's rapporteur, Godelieve Quisthoudt-Rowhol (Christian Democrat, German), set out her initial views in late September. This proposed splitting the sub-program for "unlocking the resources of the living world and the ecosystem" into two themes, "life sciences and genetic engineering" and "environment and regional development." This was broadly welcomed by Members of the European Parliament, but the Research Committee's Socialist majority is more concerned with enhancing the socioeconomic aspects of research in Europe and its implications for employment than competitiveness.

Eryl McNally MEP (Socialist, UK) said socioeconomic programs should be integrated into the framework program. She also said the Parliament should be directly involved in the program's day-to-day management; the rapporteur disagreed strongly, saying that scientific excellence should be sought in new innovative fields which the program sets as priorities, with the Parliament informed about progress rather than having a detailed involvement.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight